Bridging the Efficacy-Effectiveness Gap

While randomized controlled trials (RCTs) remain the gold standard for assessing treatment efficacy, they often lack the diversity of routine clinical practice. Consequently, real-world data (RWD) has emerged as a vital tool to bridge this gap. However, the utility of such evidence depends entirely on Real-world data quality. By providing insights into broader patient populations, high-quality RWD ensures that clinical findings are both valid and actionable for healthcare providers in India and globally.

The 5 Dimensions of Data Fitness

To support robust evidence generation, researchers must evaluate RWD through five essential quality dimensions. First, relevance determines if the data source aligns with the specific clinical question. Second, extensiveness assesses the breadth and depth of the patient population covered. Furthermore, timeliness ensures the data reflects current clinical practices and contemporary treatment landscapes. Coherence then evaluates the consistency of the data across different sources. Finally, reliability confirms that the data collection process is stable and accurate.

Ensuring High Real-World Data Quality

Establishing high Real-world data quality requires rigorous evaluation of the data source before starting a study. For instance, comparative effectiveness research during the COVID-19 pandemic highlighted how poor data quality could lead to conflicting results. By applying a fit-for-purpose framework, clinicians and researchers can generate credible evidence that informs meta-analyses and clinical guidelines. This systematic approach enhances the reliability of findings used in healthcare policy and daily decision-making.

Frequently Asked Questions

Why is RWD necessary if RCTs are the gold standard?

RCTs operate in highly controlled environments with strict inclusion criteria. RWD complements this by showing how treatments perform in diverse, real-world populations with various comorbidities and lifestyle factors.

What are the primary challenges in using RWD?

The main challenges involve data inconsistency, missing information, and potential biases in observational data. Rigorous quality assessment across relevance and reliability domains is essential to mitigate these issues.

How did COVID-19 impact the use of RWD?

The pandemic accelerated the need for timely, large-scale data to evaluate vaccines and treatments. It demonstrated that when data quality is high, RWD can provide rapid, life-saving evidence during a global health crisis.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Rivera CG et al. Evaluating treatment effectiveness: Complementing RCTs with real-world data. Am J Health Syst Pharm. 2026 Feb 09. doi: undefined. PMID: 41656514.

Yuan H et al. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making. J Clin Pharmacol. 2023 Dec 30. doi: 10.1002/jcph.2384.

Cave AJ et al. Real-world data for regulatory decision making: Challenges and possible solutions. Frontiers in Medicine. 2022. doi: 10.3389/fmed.2022.910231.